<code id='A86127C83E'></code><style id='A86127C83E'></style>
    • <acronym id='A86127C83E'></acronym>
      <center id='A86127C83E'><center id='A86127C83E'><tfoot id='A86127C83E'></tfoot></center><abbr id='A86127C83E'><dir id='A86127C83E'><tfoot id='A86127C83E'></tfoot><noframes id='A86127C83E'>

    • <optgroup id='A86127C83E'><strike id='A86127C83E'><sup id='A86127C83E'></sup></strike><code id='A86127C83E'></code></optgroup>
        1. <b id='A86127C83E'><label id='A86127C83E'><select id='A86127C83E'><dt id='A86127C83E'><span id='A86127C83E'></span></dt></select></label></b><u id='A86127C83E'></u>
          <i id='A86127C83E'><strike id='A86127C83E'><tt id='A86127C83E'><pre id='A86127C83E'></pre></tt></strike></i>

          leisure time

          leisure time

          author:leisure time    Page View:2
          Doctor Monica Bertagnolli, a white woman with short hair and bangs, sits at a hearing behind her name tag — coverage from STAT
          National Institutes of Health Director Monica Bertagnolli testifies during her Senate HELP Committee confirmation hearing on Oct. 18 in Washington. Kevin Dietsch/Getty Images

          WASHINGTON — The new National Institutes of Health director, Monica Bertagnolli, said it’s a “failure” that enrollment in government-funded clinical trials has lagged behind those funded by the pharmaceutical industry.

          “If you just look at the number of patients who go on government-funded trials, it’s been completely flat over the last decade,” she said at a meeting of the advocacy group Friends of Cancer Research. “If you go and look at the number of people who go on pharma-sponsored trials, it’s just this commitment and this increase.”

          advertisement

          A Johns Hopkins University study published in 2015 showed that the pharmaceutical industry funds six times more clinical trials than the government. Industry-sponsored trials increased 43% from 2006 to 2014, while newly registered NIH-funded trials decreased 24% over the same period.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more
          Ed Silverman on new gene therapies, biosimilars, coffee, and more
          Ed Silverman on new gene therapies, biosimilars, coffee, and more

          STAT'sEdSilvermanonstageattheSTATBreakthroughSummitin2023.SarahGonzalezforSTATIn2023,STATlaunchedabr

          read more
          Supreme Court strikes down use of affirmative action
          Supreme Court strikes down use of affirmative action

          ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

          read more

          A $475,000 price tag for a new cancer drug: crazy or meh?

          AlexHogan/STATForgetMcGregor-Mayweather.ThebiotechworldhasbeenwaitingformonthstohearaboutNovartis’s